Dermira discontinues development of acne drug after two late-stage trials fail
Dermira’s acne drug, a topical gel called DRM01, failed to meet its two primary endpoints in two phase 3 clinical trials, the company said Monday.
Dermira has suffered a surprising and catastrophic failure of its experimental acne drug.
Across two separate but identically designed Phase 3 clinical trials, Dermira’s drug, a topical gel called DRM01, did not achieve any of its endpoints when compared to an inactive control gel, the company said Monday.
is still sifting through the rubble of its failed studies, but
